Repository corticotropin (rACTH) injection (H. P. Acthar gel; Mallinckrodt Pharmaceuticals) has been under intense scrutiny for its very high cost.1,2 Because rACTH is approved for a variety of immunologic conditions prevalent in the US Medicare population, prescriptions for rACTH may have a significant financial impact on Medicare expenditures. The objectives of this study were to (1) estimate the cost of rACTH to the Medicare program, and (2) assess the within-specialty prescribing patterns for this medication.
Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN. Trends and Characteristics of US Medicare Spending on Repository Corticotropin. JAMA Intern Med. Published online September 11, 2017. doi:10.1001/jamainternmed.2017.3631